[Adiponectin and chronic viral hepatitis].
Yin
Hong-zhu
HZ
Department of Infectious Disease, Third Affiliated Hospital of Hebei Medical University, Shijiazhuang 050051, China.
Cao
Zhi-chen
ZC
D052242:Adiponectin / Q000097:blood* / Q000378:metabolism; D000998:Antiviral Agents / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D005234:Fatty Liver / Q000097:blood / Q000473:pathology; D005260:Female; D005838:Genotype; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000188:drug therapy / Q000821:virology; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D007333:Insulin Resistance; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000097:blood / Q000473:pathology; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D012367:RNA, Viral / Q000097:blood; D054419:Receptors, Adiponectin / Q000235:genetics / Q000378:metabolism
D052242:Adiponectin; D000998:Antiviral Agents; D012333:RNA, Messenger; D012367:RNA, Viral; D054419:Receptors, Adiponectin; D001219:Aspartate Aminotransferases